Clinical Trial Detail

NCT ID NCT02143466
Title AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca

lung non-small cell carcinoma


Osimertinib + Savolitinib

Osimertinib + Selumetinib

Durvalumab + Osimertinib

Age Groups: senior adult

No variant requirements are available.